Skip to content

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Working Memory in Older Adults with Subjective Cognitive Decline: A Study Using Functional Near-Infrared Spectroscopy

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Working Memory in Older Adults with Subjective Cognitive Decline: A Study Using Functional Near-Infrared Spectroscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117008
Enrollment
Unknown
Registered
2026-01-19
Start date
2026-01-22
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjective cognitive decline (SCD)

Interventions

TaVNS group:Undergo real transcutaneous auricular vagus nerve stimulation, 30 min per session, 5 times per week, for a total of 4 weeks
Sham TaVNS group:Wear electrodes at the same site but only receive a sham stimulation with extremely low current (<0.1 mA), which does not activate the vagus nerve, and the rest of the procedure is ex

Sponsors

Wuxi Huishan Rehabilitation Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 55–80 years, right-handed. 2. Meet SCD criteria: self-reported persistent memory decline =6 months compared with previous normal status, unrelated to acute events. 3. Performance on standardized neuropsychological tests (memory, processing speed/executive function, language) below the diagnostic cut-off for mild cognitive impairment (MCI). 4. Visual acuity (or corrected) >=0.8, able to perform the n-back task. 5. Intact external auditory canal and tympanic membrane, suitable for auricular electrode placement. 6. Willing to participate, provide written informed consent, and comply with follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Meets diagnostic criteria for mild cognitive impairment (MCI) or any form of dementia. 2. Any prior neurological disorder (stroke, epilepsy, Parkinson’s disease, traumatic brain injury, etc.). 3. Prior psychiatric disorders (depression, anxiety, schizophrenia, alcohol/drug dependence) or HAMD-17 score >= 7. 4. Severe visual or hearing impairment, aphasia, or upper-limb motor deficit preventing completion of cognitive tasks. 5. External auditory canal inflammation, eczema, ulceration, or inability to remove hearing aids. 6. Implanted cardiac pacemaker, defibrillator, vagus nerve stimulator, or any metallic implant. 7. Cardiovascular diseases including uncontrolled hypertension, arrhythmia, myocardial infarction, or heart failure. 8. Participation in another clinical trial within the past 3 months. 9. Non-right-handedness confirmed by the Edinburgh Handedness Inventory. 10. Any condition that the investigator deems unsuitable for participation.

Design outcomes

Primary

MeasureTime frame
Accuracy rate;Reaction time;

Secondary

MeasureTime frame
Mini-mental State Examination scale, MMSE;Montreal Cognitive Assessment Basic Version, MoCA;Auditory Language Learning Test (Huashan Version), AVLT-H;Fluency tests in animals, AFT;30 Boston Naming Test, BNT;Shape trail Making test A, STT-A-C;Shape trail Making Test B, STT-B-C;

Countries

China

Contacts

Public ContactShen Ya

Wuxi Huishan Rehabilitation Hospital

18006181931@163.com+86 180 0618 1931

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026